Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
national top stories
4
×
new york blog main
new york top stories
san diego blog main
4
×
san diego top stories
biotech
drugs
fda
san francisco blog main
san francisco top stories
boston
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
ipo
national
raleigh-durham blog main
raleigh-durham top stories
san francisco
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
acetylon pharmaceuticals
akcea therapeutics
alder biopharmaceutical
allergan
alnylam pharmaceuticals
ambys medicines
american academy of neurology
What
make
4
×
big
drug
fda
new
way
aiming
alnylam
ambys
approval
approves
arguments
biotech
biotechs
cells
chose
class
close
commercialized
companies
company
competitors
control
deadly
deal
debuted
decades
device
diseases
drugs
ema
employ
europe
firms
follows
formed
future
gene
harmful
hits
Language
Current search:
make
×
" national top stories "
×
" san diego blog main "
×
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?